Table 3.
Subject Demographics and Baseline Characteristics (Safety Analysis Set)
| Parameter | Food Effect Study (N = 16) | Kremezin/Roxadustat DDI Study Part 1 (N = 16) | Kremezin/Roxadustat DDI Study Part 2 (N = 18) |
|---|---|---|---|
| Age, y | |||
| Mean (SD) | 28.9 (5.4) | 29.3 (7.8) | 28.7 (7.3) |
| Median (range) | 27.0 (22‐39) | 28.0 (20‐44) | 29.0 (20‐44) |
| Weight, kg | |||
| Mean (SD) | 60.76 (7.15) | 64.18 (7.52) | 63.52 (5.60) |
| Median (range) | 60.25 (52.1‐75.6) | 62.55 (53.6‐79.5) | 62.15 (54.6‐75.8) |
| Height, cm | |||
| Mean (SD) | 170.73 (6.54) | 173.17 (4.97) | 171.19 (6.90) |
| Median (range) | 171.50 (159.8‐180.1) | 173.60 (163.2‐182.2) | 171.25 (153.2‐182.3) |
| BMI, kg/m2 | |||
| Mean (SD) | 20.76 (1.79) | 21.33 (2.13) | 21.62 (1.49) |
| Median (range) | 20.45 (17.7‐23.8) | 21.20 (17.9‐25.3) | 21.75 (19.2‐24.6) |
BMI, body mass index; DDI, drug‐drug interaction; SD, standard deviation.